English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: Tumor Microenvironment
We Now Know Why Killer T Cells Lose Energy Inside of Solid Tumors
Researchers at the UNC School of Medicine have found that a metabolic enzyme called Acetyl-CoA Carboxylase causes T cells to store fat when they are in solid tumors, rather than burning fat for energy.
Study shows how brain tumors make certain immune cells turn traitor
A Ludwig Cancer Research study has for the first time exhaustively analyzed neutrophils that reside in brain tumors, detailing how the immune cells support brain cancer survival and how they’re turned by the tumor microenvironment into enablers of malignant growth.
New grant seeks to parse how the variegated nature of human breast cancer tumors helps cancer cells resist treatment
The National Cancer Institute (NCI) has awarded a 5-year, $2.7 million grant to researchers at Sanford Burnham Prebys to investigate and elucidate the underlying cellular mechanisms that drive the most common form of breast cancer.
Immune and tumor cell “tug-of-war” controls anti-cancer activity
Scientists at St. Jude Children’s Research Hospital found that altering amounts of the nutrient glutamine in the tumor microenvironment could enhance or impair the immune system’s anti-cancer response.
Study discovers triple immunotherapy combination as possible treatment for pancreatic cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment (TIME) and significantly improved anti-tumor responses in preclinical models of pancreatic cancer.
MD Anderson Research Highlights for December 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a cell cycle checkpoint inhibitor with potential therapeutic effects in an ovarian cancer subtype, a telementoring program for French-speaking oncology providers in Africa, insights into the relationship between obesity and immunotherapy side effects, updates to the world’s largest cancer drug discovery knowledgebase, improvements to treatment response by blocking the EGFR pathway, and a novel noninvasive diagnostic test for immunotherapy-related kidney injury.
MD Anderson Research Highlights for October 19, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include a combination approach to overcome PARP inhibitor resistance in breast and ovarian cancers, a deeper understanding of STAT3 mutations as drivers of disease progression, insights into the “obesity paradox” in men with advanced melanoma, a prognostic model for rapidly progressing vestibular schwannoma, and a role for cellular trafficking proteins in creating a metastasis-promoting lung cancer microenvironment.
How Tumors Make Immune Cells ‘Go Bad’
Investigators from Cedars-Sinai Cancer have discovered that cancerous tumors called soft-tissue sarcomas produce a protein that switches immune cells from tumor-attacking to tumor-promoting. The study, published today in the peer-reviewed journal Cell Reports, could lead to improved treatments for soft-tissue sarcomas.
MD Anderson Research Highlights for July 13, 2022
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent basic, translational and clinical cancer research from MD Anderson experts. Current advances include new targets involved in protecting DNA replication forks and preventing inflammatory responses, a new treatment option for elderly patients with late-stage acute myeloid leukemia, insights into the breast cancer tumor microenvironment, biomarkers of response to targeted and immune therapies, a novel cellular therapy option for osteosarcoma and a new target for inducing ferroptosis in cancer cells.
Prominent Scientist Julio Aguirre-Ghiso, Ph.D., To Lead New Cancer Dormancy and Tumor Microenvironment Institute at Albert Einstein Cancer Center
Albert Einstein Cancer Center (AECC), Albert Einstein College of Medicine, and Montefiore Health System today announced that leading cancer biologist Julio Aguirre-Ghiso, Ph.D., has been named founding director of the Cancer Dormancy and Tumor Microenvironment Institute (CDTMI), director of the Gruss-Lipper Biophotonics Center, and co-leader of the AECC Tumor Microenvironment and Metastasis Program. He will also be an endowed professor of cell biology at Einstein. He will assume his new roles on October 1, 2021.
Early Lung Cancer Coopts Immune Cell Into Helping Tumors Invade the Lungs, Mount Sinai Researchers Discover
Immune cells that normally repair tissues in the body can be fooled by tumors when cancer starts forming in the lungs and instead help the tumor become invasive, according to a surprising discovery reported by Mount Sinai scientists in Nature in June.
Insight About Tumor Microenvironment Could Boost Cancer Immunotherapy
A paper published today in Nature shows how chemicals in the areas surrounding tumors – known as the tumor microenvironment – subvert the immune system and enable cancer to evade attack. These findings suggest that an existing drug could boost cancer immunotherapy.
Immune Cells Infiltrating Tumors May Play Bigger Cancer Role Than Previously Thought
UC San Diego researchers uncovered in mice how IRE1α, a molecule involved in cells’ response to stress, determines whether macrophages promote inflammation in the tumor microenvironment. Inflammation is known to promote tumor growth, making IRE1α an attractive target for drug development.